Collegium Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Collegium Pharmaceutical has been growing earnings at an average annual rate of 22.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 17.5% per year. Collegium Pharmaceutical's return on equity is 37.8%, and it has net margins of 14.8%.
Key information
22.8%
Earnings growth rate
24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 17.5% |
| Return on equity | 37.8% |
| Net Margin | 14.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet
Dec 24
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Nov 26Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Nov 14Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Revenue & Expenses Breakdown
How Collegium Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 599 | 89 | 157 | 0 |
| 30 Jun 24 | 577 | 100 | 154 | 0 |
| 31 Mar 24 | 567 | 93 | 148 | 0 |
| 31 Dec 23 | 567 | 48 | 151 | 0 |
| 30 Sep 23 | 547 | 9 | 156 | 0 |
| 30 Jun 23 | 537 | -11 | 159 | 0 |
| 31 Mar 23 | 525 | -29 | 158 | 0 |
| 31 Dec 22 | 464 | -25 | 142 | 4 |
| 30 Sep 22 | 362 | -43 | 127 | 6 |
| 30 Jun 22 | 314 | -35 | 119 | 7 |
| 31 Mar 22 | 273 | 43 | 113 | 11 |
| 31 Dec 21 | 277 | 72 | 119 | 9 |
| 30 Sep 21 | 326 | 104 | 119 | 10 |
| 30 Jun 21 | 326 | 107 | 115 | 11 |
| 31 Mar 21 | 321 | 42 | 114 | 10 |
| 31 Dec 20 | 310 | 27 | 114 | 10 |
| 30 Sep 20 | 308 | 18 | 112 | 10 |
| 30 Jun 20 | 302 | 0 | 116 | 10 |
| 31 Mar 20 | 299 | -13 | 115 | 10 |
| 31 Dec 19 | 297 | -23 | 116 | 10 |
| 30 Sep 19 | 296 | -11 | 122 | 10 |
| 30 Jun 19 | 293 | -22 | 125 | 10 |
| 31 Mar 19 | 291 | -30 | 128 | 9 |
| 31 Dec 18 | 280 | -39 | 127 | 9 |
| 30 Sep 18 | 218 | -66 | 120 | 9 |
| 30 Jun 18 | 160 | -62 | 109 | 9 |
| 31 Mar 18 | 90 | -70 | 100 | 9 |
| 31 Dec 17 | 28 | -75 | 91 | 9 |
| 30 Sep 17 | 19 | -85 | 93 | 10 |
| 30 Jun 17 | 7 | -98 | 94 | 11 |
| 31 Mar 17 | 4 | -102 | 92 | 13 |
| 31 Dec 16 | 2 | -94 | 81 | 15 |
| 30 Sep 16 | 0 | -76 | 63 | 13 |
| 30 Jun 16 | 0 | -59 | 46 | 13 |
| 31 Mar 16 | 0 | -40 | 28 | 11 |
| 31 Dec 15 | 0 | -20 | 19 | 8 |
| 30 Sep 15 | 0 | -15 | 12 | 9 |
| 30 Jun 15 | 0 | -13 | 7 | 11 |
| 31 Mar 15 | 0 | -12 | 4 | 13 |
Quality Earnings: COLL has a large one-off loss of $35.6M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: COLL's current net profit margins (14.8%) are higher than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COLL has become profitable over the past 5 years, growing earnings by 22.8% per year.
Accelerating Growth: COLL's earnings growth over the past year (882.6%) exceeds its 5-year average (22.8% per year).
Earnings vs Industry: COLL earnings growth over the past year (882.6%) exceeded the Pharmaceuticals industry 42%.
Return on Equity
High ROE: Whilst COLL's Return on Equity (37.82%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 03:41 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Collegium Pharmaceutical, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Dana Flanders | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |